Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2021

01-11-2021 | Liposarcoma | Sarcoma

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group

Authors: Carol J. Swallow, MD, PhD, Dirk C. Strauss, MD, Sylvie Bonvalot, MD, PhD, Piotr Rutkowski, MD, PhD, Anant Desai, MD, Rebecca A. Gladdy, MD, PhD, Ricardo Gonzalez, MD, David E. Gyorki, MBBS, MD, Mark Fairweather, MD, Winan J. van Houdt, MD, PhD, Eberhard Stoeckle, MD, Jae Berm Park, MD, PhD, Markus Albertsmeier, PD, Dr.med., Carolyn Nessim, MD, MSc, Kenneth Cardona, MD, Marco Fiore, MD, Andrew Hayes, MA, PhD, Dimitri Tzanis, MD, PhD, Jacek Skoczylas, MD, Samuel J. Ford, MB, ChB, PhD, Deanna Ng, MBBS, John E. Mullinax, MD, Hayden Snow, MBBS, Rick L. Haas, MD, PhD, Dario Callegaro, MD, Myles J. Smith, MB, BCh, BAO, PhD, Toufik Bouhadiba, MD, Silvia Stacchiotti, MD, Robin L. Jones, MBBS, MD(Res), Thomas DeLaney, MD, Christina L. Roland, MD, Chandrajit P. Raut, MD MSc, Alessandro Gronchi, MD, on behalf of the Transatlantic Australasian RPS Working Group (TARPSWG)

Published in: Annals of Surgical Oncology | Issue 12/2021

Login to get access

Abstract

Background

Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document.

Methods

The primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation.

Results

Management of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies.

Conclusions

Ongoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged.
Literature
1.
Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610–6.PubMedCrossRef
2.
Ferrari A, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57(6):943–9.PubMedPubMedCentralCrossRef
3.
Cormier JN, Gronchi A, Pollock RE. Soft tissue sarcomas. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, et al. (eds). Schwartz’s principles of surgery 10th edition. New York: McGraw-Hill; 2014.
4.
Dei Tos AP, Marino-Enriquez A, Pedeutour F. Soft Tissue Tumours. In: WHO Classification of Tumours Editorial Board (eds). WHO Classification of Tumours of Soft Tissue and Bone. Fifth Edition, Volume 3. Lyon: IARC Publications; 2020.
5.
Lewis JJ, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65.PubMedPubMedCentralCrossRef
6.
Stoeckle E, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92(2):359–68.PubMedCrossRef
7.
Gronchi A, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004;100(11):2448–55.PubMedCrossRef
8.
Hassan I, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004;239(2):244–50.PubMedPubMedCentralCrossRef
9.
van Dalen T, et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2007;33(2):234–8.PubMedCrossRef
10.
Lehnert T, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol. 2009;35(9):986–93.PubMedCrossRef
11.
Anaya DA, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009;249(1):137–42.PubMedCrossRef
12.
Strauss DC, et al. Surgical management of primary retroperitoneal sarcoma. Br J Surg. 2010;97(5):698–706.PubMedCrossRef
13.
Bonvalot S, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31–7.PubMedCrossRef
14.
Gronchi A, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27(1):24–30.PubMedCrossRef
15.
Bonvalot S, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17(6):1507–14.PubMedCrossRef
16.
Gronchi A, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012;23(4):1067–73.PubMedCrossRef
17.
Singer S, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358–70.PubMedPubMedCentralCrossRef
18.
Dalal KM, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244(3):381–91.PubMedPubMedCentralCrossRef
19.
20.
Almond LM, et al. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(5):571–9.PubMedCrossRef
21.
Bonvalo S, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–77.CrossRef
22.
Bonvalot S, et al. Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. Ann Surg Oncol. 2019;26(7):2286–93.PubMedCrossRef
23.
24.
Raut CP, Bonvalot S, Gronchi A. A call to action: Why sarcoma surgery needs to be centalized. Cancer. 2018;124(23):4452–4.PubMedCrossRef
25.
Gronchi A, Pollock R. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. Ann Surg Oncol. 2011;18(8):2107–10.PubMedCrossRef
26.
van Houdt WJ, et al. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration. Curr Opin Oncol. 2019;31(4):310-316.
27.
Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2015;22(1):256-63.
28.
Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2016;23(11):3531-3540.
29.
Management of metastatic retroperitoneal sarcoma. a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29(4):857–71.CrossRef
30.
31.
Heudel PE, et al. Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhone-Alpes region. Int J Clin Oncol. 2014;19(4):744–52.PubMed
32.
Keung EZ, et al. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer. 2018;124(23):4495–503.PubMedCrossRef
33.
Toulmonde M, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25(3):735–42.PubMedPubMedCentralCrossRef
34.
Villano AM, et al. Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion. J Am Coll Surg. 2020;230(1):151-160.e2.PubMedCrossRef
35.
36.
Andritsch E, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017; 110:94-105.
37.
Messiou C, Morosi C. Imaging in retroperitoneal soft tissue sarcoma. J Surg Oncol. 2018;117(1):25–32.PubMedCrossRef
38.
Messiou C, et al. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol. 2017;43(7):1191–8.PubMedCrossRef
39.
Kim DB, et al. Effect of nephrectomy for retroperitoneal sarcoma on post-operative renal function. J Surg Oncol. 2018;117(3):425–9.PubMedCrossRef
40.
Fendler WP, et al. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. Eur Radiol. 2015;25(8):2214–21.PubMedCrossRef
41.
von Mehren M, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(5):536-563.
42.
Casali PG, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29 Suppl 4:iv51–iv67.
43.
Miah AB, et al. Optimal management of primary retroperitoneal sarcoma: an update. Expert Rev Anticancer Ther. 2014;14(5):565–79.PubMedCrossRef
44.
Wilkinson MJ, et al. Percutaneous core needle biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival. Ann Surg Oncol. 2015;22(3):853–8.PubMedCrossRef
45.
Thway K, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012;36(3):462–9.PubMedCrossRef
46.
47.
Sirvent N, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31(10):1476–89.PubMedCrossRef
48.
Demicco EG, et al. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015;143(5):672–82.PubMedCrossRef
49.
Trojani M, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37–42.PubMedCrossRef
50.
Lahat G, et al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer. 2009;115(5):1081–90.PubMedCrossRef
51.
Berger-Richardson D, et al. Early and Late Complications of Percutaneous Core Needle Biopsy of Retroperitoneal Tumors at Two Tertiary Sarcoma Centers. Ann Surg Oncol. 2019;26(13):4692–8.PubMedCrossRef
52.
Van Houdt WJ, et al. Needle tract seeding following core biopsies in retroperitoneal sarcoma. Eur J Surg Oncol. 2017;43(9):1740–5.PubMedCrossRef
53.
Gronchi A, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649–55.PubMedCrossRef
54.
Martin Broto J, Le Cesne A, Reichardt P. The importance of treating by histological subtype in advanced soft tissue sarcoma. Future Oncol. 2017;13(1s):23–31.PubMedCrossRef
55.
Kirov KM, et al. Role of nutritional status in the early postoperative prognosis of patients operated for retroperitoneal liposarcoma (RLS): A single center experience. Eur J Surg Oncol. 2019;45(2):261–7.PubMedCrossRef
56.
Previtali P, et al. Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study. Ann Surg Oncol. 2019;17(10):019–08121.
57.
Bonvalot S, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012;19(9):2981–91.PubMedCrossRef
58.
Gronchi A, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263(5):1002–9.PubMedCrossRef
59.
Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. Expert Rev Anticancer Ther. 2019;19(7):613–31.PubMedCrossRef
60.
Fairweather M, et al. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol. 2018;117(1):33–41.PubMedCrossRef
61.
Tseng WW, et al. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(6):810–5.PubMedCrossRef
62.
Ng D, et al. Why were non-metastatic primary Retroperitoneal Sarcomas not resected? Connective Tissue Oncology Society Meeting Final Program 2018. Abstract ID 3042575.
63.
Andraz P, et al. Inoperable Primary Retroperitoneal Sarcomas: clinical characteristics and reasons against resection at a single referral institution. Ann Surg Oncol. 2020. Submitted.
64.
Tseng WW, et al. Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol. 2014;21(7):2136–43.PubMedCrossRef
65.
66.
Pisters PW, O’Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol. 2002;14(4):400–5.PubMedCrossRef
67.
Gilbeau L, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol. 2002;65(3):137–43.PubMedCrossRef
68.
Pawlik TM, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13(4):508–17.PubMedCrossRef
69.
Feng M, et al. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys. 2007;69(1):103–10.PubMedCrossRef
70.
Ballo MT, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67(1):158–63.PubMedCrossRef
71.
Paryani NN, et al. Multimodality local therapy for retroperitoneal sarcoma. Int J Radiat Oncol Biol Phys. 2012;82(3):1128–34.PubMedCrossRef
72.
Smith MJ, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014;110(1):165–71.PubMedCrossRef
73.
Pisters PW, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003;21(16):3092–7.PubMedCrossRef
74.
Gronchi A, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014;50(4):784–92.PubMedCrossRef
75.
Angele MK, et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg. 2014;260(5):749–54.PubMedCrossRef
76.
Issels RD, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):483–92.PubMedPubMedCentralCrossRef
77.
Radaelli S, et al. Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther. 2014;14(6):689–704.PubMedCrossRef
78.
Alektiar KM, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47(1):157–63.PubMedCrossRef
79.
Gieschen HL, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50(1):127–31.PubMedCrossRef
80.
Yoon SS, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17(6):1515–29.PubMedPubMedCentralCrossRef
81.
McBride SM, et al. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013;20(7):2140–7.PubMedCrossRef
82.
Roeder F, et al. A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma. BMC Cancer. 2012;12:287.PubMedPubMedCentralCrossRef
83.
DeLaney TF, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017;2(1):85–93.PubMedPubMedCentralCrossRef
84.
Le Pechoux C, et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol. 2013;24(3):832–7.PubMedCrossRef
85.
Haas RL, et al. Radiation therapy in retroperitoneal sarcoma management. J Surg Oncol. 2018;117(1):93–8.PubMedCrossRef
86.
Fairweather M, et al. Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas. Ann Surg Oncol. 2015;22(5):1455–63.PubMedCrossRef
87.
Dziewirski W, et al. Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol. 2006;13(2):245–52.PubMedCrossRef
88.
Raut C, et al. Why Primary Retroperitoneal Sarcoma (PRPS) Patients Undergoing Treatment At STRASS Institutions Did Not Enroll In STRASS: The STREXIT Study From EORTC STBSG And TARPSWG. Connective Tissue Oncology Society Meeting Final Program 2018. Abstract ID: 3042602.
89.
Pervaiz N, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef
90.
Woll PJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.PubMedCrossRef
91.
Gronchi A, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22.PubMedCrossRef
92.
Canter RJ, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191–7.PubMedPubMedCentralCrossRef
93.
Haas RL, et al. Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. Int J Radiat Oncol Biol Phys. 2018;101(5):1226–33.PubMedCrossRef
94.
95.
Yahya Zaidi M, Cardona K. Post-operative surveillance in soft tissue sarcoma: using tumor-specific recurrence patterns to direct approach. Chin Clin Oncol. 2018;7(4):03.
96.
Wong P, et al. Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. Cureus. 2017;9(10):e1764.PubMedPubMedCentral
97.
Callegaro D, et al. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. Br J Surg. 2015;102(9):1079–87.PubMedCrossRef
98.
Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791–6.PubMedCrossRef
99.
Anaya DA, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol. 2010;21(2):397–402.PubMedCrossRef
100.
Raut CP, et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer. 2016;122(9):1417–24.PubMedCrossRef
101.
Tan MC, et al. Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg. 2016;263(3):593–600.PubMedCrossRef
102.
Dario Callegaro, C.P.R, Deanna Ng, Dirk C Strauss, Charles Honoré, Eberhard Stoeckle, MD Sylvie Bonvalot, Rick L Haas, Nikolaos Vassos, Lorenzo Conti, Rebecca Gladdy, Mark Fairweather, Winan van Houdt, Yvonne Schrage, Frits van Coevorden, Piotr Rutkowski, Rosalba Miceli, Alessandro Gronchi, Carol Swallow. Has the outcome of patients who undergo resection of primary retroperitoneal sarcoma changed over time? A time-trends study over the past 15 years. Ann Surg Oncol. 2020 (Submitted)
103.
Khan AR, et al. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51(10):1147–56.PubMedCrossRef
Metadata
Title
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
Authors
Carol J. Swallow, MD, PhD
Dirk C. Strauss, MD
Sylvie Bonvalot, MD, PhD
Piotr Rutkowski, MD, PhD
Anant Desai, MD
Rebecca A. Gladdy, MD, PhD
Ricardo Gonzalez, MD
David E. Gyorki, MBBS, MD
Mark Fairweather, MD
Winan J. van Houdt, MD, PhD
Eberhard Stoeckle, MD
Jae Berm Park, MD, PhD
Markus Albertsmeier, PD, Dr.med.
Carolyn Nessim, MD, MSc
Kenneth Cardona, MD
Marco Fiore, MD
Andrew Hayes, MA, PhD
Dimitri Tzanis, MD, PhD
Jacek Skoczylas, MD
Samuel J. Ford, MB, ChB, PhD
Deanna Ng, MBBS
John E. Mullinax, MD
Hayden Snow, MBBS
Rick L. Haas, MD, PhD
Dario Callegaro, MD
Myles J. Smith, MB, BCh, BAO, PhD
Toufik Bouhadiba, MD
Silvia Stacchiotti, MD
Robin L. Jones, MBBS, MD(Res)
Thomas DeLaney, MD
Christina L. Roland, MD
Chandrajit P. Raut, MD MSc
Alessandro Gronchi, MD
on behalf of the Transatlantic Australasian RPS Working Group (TARPSWG)
Publication date
01-11-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-09654-z

Other articles of this Issue 12/2021

Annals of Surgical Oncology 12/2021 Go to the issue

Hepatobiliary Tumors

Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group

Thoracic Oncology

Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma

Sarcoma

Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent

Hepatobiliary Tumors

A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in this Modern Era

Thoracic Oncology

Survival of Octogenarians with Early-Stage Non-small Cell Lung Cancer is Comparable Between Wedge Resection and Lobectomy/Segmentectomy: JACS1303

ASO Author Reflections

ASO Author Reflections: Predicting Postoperative Resolution of Hypertension in Primary Hyperaldosteronism